Related Experiment Video
Updated: Jun 19, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease
William C Cromwell1, Thomas A Barringer
1Division of Atherosclerosis and Lipoprotein Disorders, Presbyterian Cardiovascular Institute, 125 Baldwin Avenue, Suite 200, Charlotte, NC 28204, USA. wcromwell@gmail.com
Insights
Measuring low-density lipoprotein (LDL) cholesterol is key in practice. Apo B and LDL particle number are better predictors of coronary heart disease risk than LDL cholesterol alone.
Area of Science:
- Cardiology
- Clinical Lipidology
- Preventive Medicine
Background:
- Low-density lipoprotein (LDL) management is crucial in clinical practice.
- Traditional LDL cholesterol (LDLC) measurement has limitations due to particle variability.
- Discrepancies exist between LDLC and LDL particle measures like apolipoprotein B-100 (apo B) or NMR LDL particle number (LDL-P).
Purpose of the Study:
- To review the rationale for using LDL particle measures in clinical practice.
- To discuss the superiority of apo B and LDL-P in predicting coronary heart disease (CHD) risk.
- To provide a model for integrating LDL particle measures into therapeutic strategies.
Main Methods:
- Review of existing studies on LDL measurement and CHD risk prediction.
- Analysis of the relationship between LDLC, apo B, and LDL-P.
- Evaluation of current clinical recommendations regarding LDL targets.
Main Results:
- Apo B and LDL-P are consistently superior predictors of CHD risk.
- Apo B and LDL-P better indicate reduced CHD risk during lipid-lowering therapy.
- Recent guidelines recommend apo B or LDL-P as therapeutic targets alongside LDLC.
Conclusions:
- LDL particle measures, specifically apo B and LDL-P, offer superior risk assessment compared to LDLC.
- Integrating LDL particle assessment into clinical practice is recommended for improved CHD risk management.
- Further research may refine the clinical application of LDL particle-based therapies.
Abstract:
Managing low-density lipoprotein (LDL) is an integral part of clinical practice. What remains controversial is whether we are using the best measure of LDL quantity for this purpose. Historically, the cholesterol content of LDL particles (LDLC) has been used to express LDL quantity. However, because of variability in the cholesterol carried in LDL particles, frequent disagreement occurs between LDLC and particle measures of LDL quantity, including apolipoprotein B-100 (apo B) or nuclear magnetic resonance (NMR) LDL particle number (LDL-P). Studies consistently demonstrate apo B and LDL-P are superior predictors of coronary heart disease (CHD) risk and superior indicators of low CHD risk on lipid-lowering therapy. Recent recommendations advocate that, in addition to LDLC and non-high-density lipoprotein cholesterol, apo B (or NMR LDL-P) be used as a target of therapy. This article reviews the rationale supporting these recommendations and provides a model for integrating LDL particle measures in clinical practice.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease V: Interprofessional Care
Cholesterol: Significance and Regulation
Considering cholesterol and...
